<DOC>
	<DOCNO>NCT00386139</DOCNO>
	<brief_summary>Evaluate diastolic blood pressure lower effect combination aliskiren 300 mg HCTZ ( 12.5 mg 25 mg ) hypertensive patient show sufficient blood pressure response aliskiren 300 mg .</brief_summary>
	<brief_title>A Safety Efficacy Trial Combination Aliskiren / Hydrochlorothiazide ( HCTZ ) ( 300/12.5 mg 300/25 mg ) Compared Aliskiren 300 mg Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female outpatient 18 year old old . Patients diagnosis hypertension . Patients eligible consent participate study Severe hypertension Previous current diagnosis heart failure . History hypertensive encephalopathy cerebrovascular accident , transient ischemic cerebral attack ( TIA ) , myocardial infarction , coronary bypass surgery , percutaneous coronary intervention ( PCI ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diastolic</keyword>
	<keyword>systolic</keyword>
	<keyword>hypertension</keyword>
	<keyword>aliskiren</keyword>
	<keyword>blood pressure</keyword>
	<keyword>hydrochlorothiazide , HCTZ</keyword>
</DOC>